Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given an average recommendation of “Hold” by the twenty-one research firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $124.11.

A number of equities research analysts have weighed in on ZBH shares. Truist Financial lifted their target price on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. Oppenheimer decreased their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Barclays decreased their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Finally, Royal Bank of Canada lifted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $108.27 on Thursday. Zimmer Biomet has a 52-week low of $100.67 and a 52-week high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The firm has a market capitalization of $21.55 billion, a P/E ratio of 20.58, a P/E/G ratio of 1.88 and a beta of 1.02. The stock has a 50 day moving average price of $107.82 and a 200 day moving average price of $108.20.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s payout ratio is presently 18.25%.

Institutional Trading of Zimmer Biomet

Large investors have recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at about $25,000. Dunhill Financial LLC lifted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $31,000. Finally, Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.